LEXICON PHARMACEUTICALS INC stock forecast: down to 1.64 USD LXRX stock price prognosis

STOCK

Forecast for Fri 19 Jul 2024 price 2.14

LEXICON PHARMACEUTICALS INC stock price forecast for further price development down to -22.65% (time horizon: 1 day) and price target of 1.64 USD. Short-term (time horizon: 2 weeks) LEXICON PHARMACEUTICALS INC share price prediction for 2024-07-19 with daily closed price projections

Key Facts

Symbol LXRX 

ISIN US5288723027 

CUSIP 528872302


Currency USD


Category Pharmaceutical Preparations

Forecast price change %

Relative Strength Index (RSI)

Finance numbers

Revenue 16,023,000.0


Earnings per share -0.05


On our site we made daily predictions for finance products based on statistical analysis. You can export / download forecasted data as CSV file, no login required. The information can be used for day trading.

Summerized Form 10-K with GPT-2

As of March 6, 2021, 144,354,161 shares of common stock were outstanding. The effects of LX9211 will be assessed over an 11-week evaluation period. Certain patient-reported outcome measures will also be assessed. Insulin therapy was optimized in patients over a 6-week period prior to dosing. Bristol-Myers Squibb extended the target discovery term of the alliance in May 2006. Our quality department audits these suppliers on a periodic basis. Submission of an IND may not result in FDA authorization to commence a clinical trial. These laws could create liability for us or increase our cost of doing business. He received his B.A. and J.D. from the University of Texas. In some cases, we or our collaborators may not be able to complete the trial at all. As of December 31, 2020, we had an accumulated deficit of $1.4 billion. Any of our present or future collaborators may not perform their obligations as expected. In some cases, patents have issued, and may issue in the future, from these applications. Invus has designated three of the nine current members of our board of directors. Excessive volatility may continue for an extended period of time. We filed a response brief on February 18, 2021. As of March 6, 2021, there were approximately 327 holders of record of our common stock. Selected Financial Data Not applicable.35Item 7. Service fees were also deducted from product sales as they were earned. The allowance for chargeback was based on known sales to contracted customers. The drug development process takes many years to complete. There were no significant impairments of long-lived assets in 2019 or 2018. Accordingly, we have not had any material exposure to foreign currency rate fluctuations. We conducted our audits in accordance with the standards of the PCAOB. We believe that our audits provide a reasonable basis for our opinion. Net realized gains and losses, interest and dividends are included in interest income. See Note 4, Asset Sale, for additional information relating to inventory. The Company has not experienced any significant credit losses to date. In 2020, customers in the United States represented 98% of revenue. Maintenance, repairs and minor replacements are charged to expense as incurred. The impairment reduced the remaining book value to zero. The Company expected that its customers would earn prompt payment discounts. The allowance for rebates is based on statutory discount rates and expected utilization. Product shipping and handling costs were included in cost of sales. The Black-Scholes option-pricing model requires the input of subjective assumptions. Historical data is used to estimate the expected option life for each group. The Company uses the liability method in accounting for income taxes. The Company incurred and recognized severance charges of approximate $5.5 million. Refer to Note 10, Debt Obligations, for fair value measurements of debt obligations. The federal and state NOL carryforwards will begin to expire in 2024. This test did not result in an impairment of goodwill.10. At December 31, 2020, the intrinsic value of exercisable stock options was zero. As such, the Company did not include those payments in the allocable consideration. Our board of directors currently consists of nine members, divided into three classes. the Sarbanes-Oxley Act, 18 U.S.C. § 1514A, et seq., the New Jersey Family Leave Act, N.J.S.A. 34:11B-1, et seq., Employee specifically waives any rights or claims under the ADEA&

Summerized Form 10-K with GPT-2 https://www.sec.gov/Archives/edgar/data/1062822/000106282221000013/0001062822-21-000013.txt
Candlestick patterns

Candlestick patterns can be used as additional information for price prediction. Following list show which pattern applies on latest price information.

  • Meta analyst score 39.06/100
    • Good financial position.
    • Historical view, profit is growing.
    • Company revenue is not growing faster compared with the industry.

Institutional ownership list is based on filling form information

Holding name Date Amount
A - BARCLAYS PLC 2023-06-30 37669
A - OSAIC HOLDINGS, INC. 2023-06-30 6368
China Universal Asset Management Co., Ltd. 2023-06-30 2485
VOYA INVESTMENT MANAGEMENT LLC 2022-09-30 32681
MetLife Investment Management, LLC 2022-12-31 21835

Fund ownership list is based on filling form information

Fund name Date Amount Profile
SCHWAB STRATEGIC TRUST 2023-11-30 547072 Long
SCHWAB STRATEGIC TRUST 2023-11-30 54607 Long
MORGAN STANLEY PATHWAY FUNDS 2023-11-30 2519 Long
ProShares Trust 2023-11-30 15620 Long
ProShares Trust 2023-11-30 7466 Long

Insider trading for LEXICON PHARMACEUTICALS INC

CIK Name Date Action T-Test 1day T-Test 7day T-Test 14day T-Test 30day
1612528 Coats Lonnel 2023-11-10 BUY Accept Accept Accept Accept
1053890 Debbane Raymond 2023-10-11 BUY Reject Reject Reject Reject
1225767 Wade Jeffrey L 2023-09-14 BUY Accept Accept Accept Accept
1404553 Invus Advisors, L.l.c. 2023-06-05 BUY Reject Accept Accept Accept
1902760 Mcdermott Wendy 2023-08-04 BUY Accept Accept Accept Accept


Bollinger Bollinger Bands for LEXICON PHARMACEUTICALS INC can provide the information where the market is moving based on price information.


LEXICON PHARMACEUTICALS INC Short Volume Ratio is shown in the diagram. Short volume sales can be seen as an investor sentiment.



Converting prices to returns LEXICON PHARMACEUTICALS INC.


On-Balance Volume information for LEXICON PHARMACEUTICALS INC. On-Balance Volume information can be an indicator for bullish or bearish outcome.



Accumulation / Distribution (A/D) indicator information for LEXICON PHARMACEUTICALS INC. The indicator identify divergences between price and volume flow.


Aroon Oscillator information for LEXICON PHARMACEUTICALS INC. The trend-following indicator can show the strengh of a current trend and likelihood that trend can continue.


Average Directional Index (ADX) information for LEXICON PHARMACEUTICALS INC. The index can be used to identify the strengh of a trend.


Moving Average Convergence Divergence (MACD) for LEXICON PHARMACEUTICALS INC. The indicator helps to predict trend direction and the momentum of the trend.


Stochastic Oscillator as momentum indicator for LEXICON PHARMACEUTICALS INC. The indicator is useful for identifying overbought and oversold levels.


Relative Strength Index (RSI) for LEXICON PHARMACEUTICALS INC. RSI is a momentum oscillator that measures the speed and change of price development. The momentum indicator was created by analyst Welles Wilder. The result compares recent gains and losses over restricted time period. Primary usage of the indicator is to identify overbought or oversold signals. When RSI indicator reaches a value of 70 it could mean that speculators should consider selling, suggests Wilder and Chong. Or vice versa when selling excess at which the RSI Indicators show a value of 30 [ Relative Strength Index for Developing Effective Trading Strategies in Constructing Optimal Portfolio ].


Heikin Ashi trading signals are generated based on the Heikin Ashi candles, which are a type of candlestick that smooths out the price action and can help to identify trends. Heikin Ashi signals can be used to identify both long and short trading opportunities.


The awesome oscillator is a momentum indicator that measures the speed and strength of price movements. It is calculated by subtracting a 34-period simple moving average (SMA) from a 5-period SMA.


The Parabolic SAR indicator is a trend-following indicator that uses a series of dots to indicate when a trend is likely to reverse. The Parabolic SAR is a lagging indicator, meaning that it does not predict reversals, but rather confirms them after they have already occurred.


Moving Average Crossover


52W High 52W Low Market Cap

Similar shares


LEXICON PHARMACEUTICALS INC on Nasdaq

LEXICON PHARMACEUTICALS INC on finviz

Figure below show the stock predictions.
Date Closing price Prediction was updated
2024-05-27 1.64 2024-05-25 06:09
2024-05-28 1.64 2024-05-25 06:09
2024-05-29 1.66 2024-05-25 06:09
2024-05-30 1.67 2024-05-25 06:09
2024-06-06 1.72 2024-05-25 06:09
2024-06-05 1.71 2024-05-25 06:09
2024-05-31 1.68 2024-05-25 06:09
2024-06-03 1.69 2024-05-25 06:09
2024-06-04 1.70 2024-05-25 06:09
2024-06-10 1.72 2024-05-25 06:09
2024-06-11 1.73 2024-05-25 06:09
2024-06-07 1.72 2024-05-25 06:09
2024-06-12 1.75 2024-05-25 06:09
2024-06-13 1.77 2024-05-25 06:09
2024-06-14 1.78 2024-05-25 06:09
2024-06-19 1.83 2024-05-25 06:09
2024-06-20 1.85 2024-05-25 06:09
2024-06-21 1.86 2024-05-25 06:09
2024-06-17 1.80 2024-05-25 06:09
2024-06-18 1.81 2024-05-25 06:09
2024-07-05 2.01 2024-05-25 06:09
2024-06-26 1.91 2024-05-25 06:09
2024-07-10 2.05 2024-05-25 06:09
2024-07-12 2.08 2024-05-25 06:09
2024-07-11 2.06 2024-05-25 06:09
2024-07-04 1.99 2024-05-25 06:09
2024-07-08 2.02 2024-05-25 06:09
2024-06-24 1.88 2024-05-25 06:09
2024-06-25 1.89 2024-05-25 06:09
2024-06-27 1.92 2024-05-25 06:09
2024-07-01 1.95 2024-05-25 06:09
2024-07-02 1.96 2024-05-25 06:09
2024-07-03 1.98 2024-05-25 06:09
2024-07-15 2.09 2024-05-25 06:09
2024-07-16 2.10 2024-05-25 06:09
2024-06-28 1.93 2024-05-25 06:09
2024-07-17 2.12 2024-05-25 06:09
2024-07-19 2.14 2024-05-25 06:09
2024-07-09 2.04 2024-05-25 06:09
2024-07-18 2.13 2024-05-25 06:09

The forecast (dashed curve) of the share price performance is based on historical data. Our forecast model is based on mathematical, statistical methods. The website offers price forecasts and analysis tools for equities and other securities, which are exclusively based on the prices of these securities in the past. Information about these prices is provided to us by third parties. Although we believe, If we believe that our sources are reliable, we cannot guarantee the accuracy, completeness, timeliness and correct sequencing of this information. We do not investigate the issuers of the securities to which our forecasts relate, nor do we consider any financial data or other data of such issuers with the exception of the past prices of the securities. Therefore, our forecasts do not constitute an analysis of other commercial or financial factors or circumstances, that may be relevant for future security price flows. Investments require additional considerations. Our forecasts cannot reflect the specific situation. Experience and risk profile of an individual investor or the tax implications an investment may have for the investor. Although we believe that our mathematical models are a tool to try to explore the possibility for future price development with the help of past performance, such developments are subject to a multitude of different influences. and therefore not really predictable. We cannot guarantee the success of any investment you make based on the information published here. This website is for information purposes only. All information and data on this website cannot be guaranteed to be accurate, accuracy, completeness and appropriateness - neither explicit nor implicit.